Key Points – Twist Bioscience reported strong fiscal Q3 growth: Revenue rose 23% year over year to $118.4 million, led by DNA Synthesis and Protein Solutions growth of 39% and NGS Applications growth of 12%.
The company raised fiscal 2026 revenue guidance to $456 million–$457 million. – AI-enabled drug discovery is becoming a major growth driver
Management said demand is expanding as customers repeatedly use AI models in therapeutic design and expressed confidence in achieving at least triple-digit order growth in both fiscal 2026 and fiscal 2027. – Profitability is improving despite planned investments: Gross margin increased to 52.8%, while Twist reiterated its expectation to reach adjusted EBITDA breakeven in fiscal Q4. The company also launched its Complex Genes offering after early-access customers ordered more than 1,800 constructs. Twist Bioscience (NASDAQ:TWST) reported fiscal 2026 third-quarter revenue of $118.4 million, up 23% from a year earlier, marking its 14th consecutive quarter of growth.
The company raised its full-year revenue outlook and said it remains on track to reach adjusted EBITDA breakeven in the fiscal fourth quarter. Chief Executive Officer and Co-Founder Emily Leproust said growth was supported by demand across the company’s DNA synthesis, protein solutions and next-generation sequencing businesses, with AI-enabled drug discovery emerging as a significant driver. “Today, we are seeing that opportunity mature into a durable growth engine,” Leproust said of AI-enabled discovery. Revenue Growth Led by DNA Synthesis and Therapeutics DNA Synthesis and Protein Solutions revenue rose 39% year over year to $56.6 million during the quarter, while NGS Applications revenue increased 12% to approximately $61.8 million.